Aurora Cannabis Slams False Reports On MedLeaf, MediPharm Deals; Stock Sinks

Retail chatter around Aurora Cannabis spiked Thursday after the company denied online reports claiming it had entered into agreements with MedLeaf Therapeutics and MediPharm GmbH.

The stock closed down 20.4% at $4.68 on Wednesday, before edging up 0.4% to $4.7 in after-hours trading.

Aurora Cannabis said it has not held any talks with MedLeaf Therapeutics or MediPharm GmbH and dismissed reports suggesting otherwise, stating it has made no announcements or filings related to any such agreements. 

The now-disputed reports alleged that Aurora was acquiring New Zealand-based MedLeaf and had entered a distribution deal with Germany's MediPharm GmbH for medical cannabis across EU markets. Both articles were reportedly generated “with the support of AI” and included editorial review, according to disclosures on the publishing platform.

Aurora said it is launching an internal investigation into how the misinformation surfaced and reiterated that it does not own any material non-public information. 

On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.

One user attributed the recent dip in Aurora Cannabis shares to misinformation rather than company fundamentals, suggesting the stock could rebound sharply as short sellers exit losing positions. 

Another user signaled they were eyeing a potential entry point, anticipating a further pullback before a possible bounce.

Aurora Cannabis stock has risen 4% so far in 2025.

For updates and corrections, email newsroom[at]stocktwits[dot]com.